{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+%28Phase+I%29&page=2", "query": { "condition": "Solid Tumor (Phase I)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 3263, "total_pages": 327, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+%28Phase+I%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+%28Phase+I%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T17:48:19.786Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04572451", "title": "Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Unresectable Solid Tumors", "Neoplasms", "Neoplasms by Histologic Type", "Neoplasms by Site", "Antineoplastic Agents, Immunological", "Antineoplastic Agents", "Immune Checkpoint Inhibitors", "Molecular Mechanisms of Pharmacological Action", "Nivolumab" ], "interventions": [ { "name": "nivolumab", "type": "DRUG" }, { "name": "BMS-986253", "type": "DRUG" }, { "name": "Stereotactic Body Radiotherapy (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Yana Najjar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-11-29", "completion_date": "2027-08-05", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-16T17:48:19.786Z", "location_count": 2, "location_summary": "Chicago, Illinois • Pittsburgh, Pennsylvania", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04572451" }, { "nct_id": "NCT00020267", "title": "Vaccine Therapy in Treating Patients With Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Adult Soft Tissue Sarcoma", "Colorectal Cancer", "Bone Cancer", "Ovarian Sarcoma", "Melanoma", "Colon Cancer", "Rectal Cancer", "Breast Cancer", "Eye Cancer", "Uterine Sarcoma" ], "interventions": [ { "name": "interleukin-2", "type": "DRUG" }, { "name": "MAGE-12 peptide vaccine", "type": "DRUG" }, { "name": "Montanide ISA-51", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": null, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "2000-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-10-16T17:48:19.786Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020267" }, { "nct_id": "NCT03746431", "title": "A Phase 1 Study of [225Ac]-FPI-1434 Injection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumours", "Endometrial Cancer", "Cervical Cancer", "Ovarian Cancer", "Breast Cancer", "Triple Negative Breast Cancer (TNBC)", "HER2-negative Breast Cancer", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Adrenocortical Carcinoma", "Uveal Melanoma" ], "interventions": [ { "name": "[111In]-FPI-1547 Injection", "type": "DRUG" }, { "name": "[225Ac]-FPI-1434 Injection multi-dose", "type": "DRUG" }, { "name": "FPI-1175 Infusion", "type": "BIOLOGICAL" }, { "name": "[225Ac]-FPI-1434 Injection single-dose", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Fusion Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-01-17", "completion_date": "2025-12-03", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-10-16T17:48:19.786Z", "location_count": 7, "location_summary": "Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03746431" }, { "nct_id": "NCT00004075", "title": "17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-08", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2011-08-03", "last_synced_at": "2026-10-16T17:48:19.786Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004075" }, { "nct_id": "NCT06823167", "title": "A Phase 1 Study of IM-1021 in Participants With Advanced Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Malignancies", "Hematologic Malignancies" ], "interventions": [ { "name": "IM-1021", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immunome, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2025-02-26", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-16T17:48:19.786Z", "location_count": 19, "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 16 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06823167" }, { "nct_id": "NCT04152499", "title": "Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Epithelial Ovarian Cancer", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Urothelial Carcinoma", "Non-Small Cell Lung Cancer", "Small-Cell Lung Cancer", "Endometrial Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Breast Cancer", "Cervical Cancer" ], "interventions": [ { "name": "SKB264", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Klus Pharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1410, "start_date": "2020-02-28", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-16T17:48:19.786Z", "location_count": 10, "location_summary": "Glendale, California • Los Angeles, California • Sarasota, Florida + 7 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT04152499" }, { "nct_id": "NCT03780517", "title": "Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Nonhaematologic Malignancies" ], "interventions": [ { "name": "BOS172738", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boston Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2018-12-12", "completion_date": "2023-09-26", "has_results": false, "last_update_posted_date": "2023-10-30", "last_synced_at": "2026-10-16T17:48:19.786Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03780517" }, { "nct_id": "NCT00207025", "title": "A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors" ], "interventions": [ { "name": "BMS-275183", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2004-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-03-02", "last_synced_at": "2026-10-16T17:48:19.786Z", "location_count": 2, "location_summary": "Detroit, Michigan • Pittsburgh, Pennsylvania", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00207025" }, { "nct_id": "NCT06898450", "title": "A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors Cancer", "MSI-H Cancer" ], "interventions": [ { "name": "NDI-219216", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nimbus Wadjet, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 134, "start_date": "2025-03-31", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-16T17:48:19.786Z", "location_count": 11, "location_summary": "Los Angeles, California • Chicago, Illinois • Louisville, Kentucky + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Ithaca", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06898450" }, { "nct_id": "NCT07335497", "title": "CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced / Metastatic Solid Tumors" ], "interventions": [ { "name": "CR-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Crescent Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 290, "start_date": "2026-02-17", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-16T17:48:19.786Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07335497" } ] }